Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,525

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Egger, Matthias, May, Margaret, Chêne, Geneviève, Phillips, Andrew N, Ledergerber, Bruno, Dabis, François, Costagliola, Dominique, Monforte, Antonella D'Arminio, de Wolf, Frank, Reiss, Peter, Lundgren, Jens D, Justice, Amy C, Staszewski, Schlomo, Leport, Catherine, Hogg, Robert S, Sabin, Caroline A, Gill, M John, Salzberger, Bernd, Sterne, Jonathan AC·2002·The Lancet
DOI 10.1016/s0140-6736(02)09411-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(02)09411-4

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 48

  1. Egger, 1997, Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study, BMJ, 315, 1194, 10.1136/bmj.315.7117.1194 · DOI · Paper page
  2. Hogg, 1999, Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens, Can Med Assoc J, 160, 659
  3. Mocroft, 1998, Changing patterns of mortality across Europe in patients infected with HIV-1, Lancet, 352, 1725, 10.1016/S0140-6736(98)03201-2 · DOI · Paper page
  4. Farmer, 2001, Community-based approaches to HIV treatment in resource-poor settings, Lancet, 358, 404, 10.1016/S0140-6736(01)05550-7 · DOI · Paper page
  5. Mellors, 1997, Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection, Ann Intern Med, 126, 946, 10.7326/0003-4819-126-12-199706150-00003 · DOI · Paper page
  6. 2000, Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis, Lancet, 355, 1131, 10.1016/S0140-6736(00)02061-4 · DOI · Paper page
  7. Hughes, 1998, CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group, AIDS, 12, 1823, 10.1097/00002030-199814000-00014 · DOI
  8. 2000, Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis, AIDS Res Hum Retroviruses, 16, 1123, 10.1089/088922200414965 · DOI
  9. Grabar, 2000, Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy, Ann Intern Med, 133, 401, 10.7326/0003-4819-133-6-200009190-00007 · DOI · Paper page
  10. D'Arminio, 2000, Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients, AIDS, 14, 499, 10.1097/00002030-200003310-00005 · DOI · Paper page
  11. Nieuwkerk, 2001, Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study, Arch Intern Med, 161, 1962, 10.1001/archinte.161.16.1962 · DOI · Paper page
  12. Lundgren, 1997, Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients, J Acquir Immune Defic Syndr, 16, 153, 10.1097/00042560-199711010-00003 · DOI
  13. Becker, 2001, Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort, J Acquir Immune Defic Syndr, 26, 72, 10.1097/00126334-200101010-00011 · DOI
  14. Brodt, 1997, Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy, AIDS, 11, 1731, 10.1097/00002030-199714000-00010 · DOI · Paper page
  15. Le Moing, 2002, Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen, J Infect Dis, 185, 471, 10.1086/338929 · doi:10.1086/338929
  16. Binquet, 2001, Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine cohort, 1996–1997, Am J Epidemiol, 153, 386, 10.1093/aje/153.4.386 · doi:10.1093/aje/153.4.386
  17. Mocroft, 1999, The changing pattern of admissions to a London hospital of patients with HIV: 1988–1997. Royal Free Centre for HIV Medicine, AIDS, 13, 1255, 10.1097/00002030-199907090-00016 · doi:10.1097/00002030-199907090-00016
  18. Mocroft, 1998, Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor, AIDS, 12, 2161, 10.1097/00002030-199816000-00011 · doi:10.1097/00002030-199816000-00011
  19. Fatkenheuer, 1997, Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients, AIDS, 11, F113, 10.1097/00002030-199714000-00001 · doi:10.1097/00002030-199714000-00001
  20. 1992, Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, MMWR Morb Mortal Wkly Rep, 41, 1
  21. Royston, 2001, Flexible alternatives to the Cox model, Stata J, 1, 1, 10.1177/1536867X0100100101 · DOI · Paper page
  22. Spiegelhalter, 2002, Bayesian measures of model complexity and fit, J R Stat Soc B, 64, 1, 10.1111/1467-9868.00353 · DOI · Paper page
  23. Justice, 1999, Assessing the generalizability of prognostic information, Ann Intern Med, 130, 515, 10.7326/0003-4819-130-6-199903160-00016 · DOI · Paper page
  24. Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
  25. Lundgren, 2002, A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study, J Infect Dis, 185, 178, 10.1086/338267 · DOI
  26. Fellay, 2002, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, Lancet, 359, 30, 10.1016/S0140-6736(02)07276-8 · DOI · Paper page
  27. Valdez, 1999, Association of the CCR5delta32 mutation with improved response to antiretroviral therapy, JAMA, 282, 734, 10.1001/jama.282.8.734 · doi:10.1001/jama.282.8.734
  28. Schuurman, 1996, Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma, J Clin Microbiol, 34, 3016, 10.1128/jcm.34.12.3016-3022.1996 · doi:10.1128/jcm.34.12.3016-3022.1996
  29. Frisch, 2001, Association of cancer with AIDS-related immunosuppression in adults, JAMA, 285, 1736, 10.1001/jama.285.13.1736 · DOI · Paper page
  30. Ledergerber, 1999, Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study, Lancet, 353, 863, 10.1016/S0140-6736(99)01122-8 · DOI · Paper page
  31. Phillips, 2001, HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load, JAMA, 286, 2560, 10.1001/jama.286.20.2560 · doi:10.1001/jama.286.20.2560
  32. Hogg, 2001, Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy, JAMA, 286, 2568, 10.1001/jama.286.20.2568 · DOI · Paper page
  33. Phillips, 1991, More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts, J Acquir Immune Defic Syndr, 4, 970
  34. Viard, 2001, Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study, J Infect Dis, 183, 1290, 10.1086/319678 · DOI · Paper page
  35. Yamashita, 2001, Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study, AIDS, 15, 735, 10.1097/00002030-200104130-00009 · DOI · Paper page
  36. Eskild, 1993, Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users, Int J Epidemiol, 22, 315, 10.1093/ije/22.2.315 · DOI
  37. Selwyn, 1989, Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program, Am J Public Health, 79, 1358, 10.2105/AJPH.79.10.1358 · DOI
  38. Greub, 2000, Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study, Lancet, 356, 1800, 10.1016/S0140-6736(00)03232-3 · DOI · Paper page
  39. Saves, 1999, Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996–1998, AIDS, 13, F115, 10.1097/00002030-199912030-00002 · DOI
  40. Chaisson, 1998, Impact of opportunistic disease on survival in patients with HIV infection, AIDS, 12, 29, 10.1097/00002030-199801000-00004 · DOI · Paper page
  41. Moore, 2001, Gender differences in virologic response to treatment in an HIV-positive population: a cohort study, J Acquir Immune Defic Syndr, 26, 159, 10.1097/00126334-200102010-00008 · DOI
  42. Gulick, 1997, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy, N Engl J Med, 337, 734, 10.1056/NEJM199709113371102 · DOI · Paper page
  43. Hammer, 1997, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, N Engl J Med, 337, 725, 10.1056/NEJM199709113371101 · DOI · Paper page
  44. Cameron, 1998, Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, Lancet, 351, 543, 10.1016/S0140-6736(97)04161-5 · DOI · Paper page
  45. Lederman, 2000, Immune restoration with antiretroviral therapies: implications for clinical management, JAMA, 284, 223, 10.1001/jama.284.2.223 · doi:10.1001/jama.284.2.223
  46. Harrington, 2000, Hit HIV-1 hard, but only when necessary, Lancet, 355, 2147, 10.1016/S0140-6736(00)02388-6 · DOI
  47. Egger, 2001, Highly active antiretroviral therapy and coronary heart disease: the need for perspective, AIDS, 15, S193, 10.1097/00002030-200100005-00023 · DOI
  48. Miettinen, 1983, The need for randomization in the study of intended effects, Stat Med, 2, 267, 10.1002/sim.4780020222 · DOI · Paper page

Cited by

See all 1,525

Metadata

Authors
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., Lundgren, J. D., Justice, A. C., Staszewski, S., Leport, C., Hogg, R. S., Sabin, C. A., Gill, M. J., Salzberger, B., & Sterne, J. A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2002-07
Volume
360
Issue
9327
Pages
119-129
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(02)09411-4
OpenAlex
W1964622370
Cited by
1,525
References
1
FWCI
52.26
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Abbott Laboratories
  • Roche

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. https://app.cochat.ai/papers/10.1016/s0140-6736(02)09411-4
The paper
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., Lundgren, J. D., Justice, A. C., Staszewski, S., Leport, C., Hogg, R. S., Sabin, C. A., Gill, M. J., Salzberger, B., & Sterne, J. A. (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet. https://doi.org/10.1016/s0140-6736(02)09411-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.